CYP 2.38% 21.5¢ cynata therapeutics limited

Ann: Trading Halt-CYP.AX, page-10

  1. 715 Posts.
    lightbulb Created with Sketch. 19
    7 weeks ago.

    ASX ANNOUNCEMENT 1 August 2016
    Cynata Files Application to Commence Phase 1 Clinical Trial



    “The application to commence our Phase 1 study with the MHRA represents the culmination of an intensive program of manufacturing process development, safety evaluation and proof-of-concept studies. The successful outcomes from our product development activities over the past two-and-a- half years have allowed us to move things forward,” said Cynata Vice President of Product Development, Dr Kilian Kelly. “We have been very pleased with the result of our pre-clinical program and are eager to advance to an initial clinical study with our induced pluripotent stem cell (iPSC) derived MSC therapeutic product, CYP-001.”

    All Positive.
 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
(20min delay)
Last
21.5¢
Change
0.005(2.38%)
Mkt cap ! $38.81M
Open High Low Value Volume
21.5¢ 21.5¢ 21.5¢ $1.505K 7K

Buyers (Bids)

No. Vol. Price($)
6 238227 20.0¢
 

Sellers (Offers)

Price($) Vol. No.
22.0¢ 27500 1
View Market Depth
Last trade - 15.38pm 22/08/2024 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.